At a critical juncture where the scientific instrument industry centers on technological innovation and capital trends, an informative industry sharing session was held as scheduled. The Beijing Conference and Exhibition on Instrumental Analysis 2025 (BCEIA 2025) grandly opened on September 10, 2025. As an annual landmark exhibition in the scientific instrument sector, it brought together industry practitioners, investment institutions and technological pioneers.
As a leading domestic enterprise specializing in high-end liquid chromatography technologies, Zhang Xin, Co-founder & CEO of Chromai, was invited to the Scientific Instrument Investment and Financing Seminar co-hosted by China Association for Instrumental Analysis and Instrument Learning Network. He shared practical insights covering corporate financing practices, primary market investment trends and industry pain points, clarifying industry uncertainties and helping participants grasp core industry logic.
At the start of the sharing, Zhang Xin outlined Chromai’s core business layout and full-chain roadmap spanning R&D to market commercialization, enabling attendees to gain a clear picture of the company’s development trajectory. More importantly, he thoroughly analyzed the underlying logic of financing, offering replicable financing strategies for peer enterprises in the sector.
Subsequently, Zhang Xin delivered in-depth trend analysis based on H1 2025 primary market data. Overall, primary market investment has grown more rational, with capital flowing toward sectors boasting core technologies and viable business models. When zooming in on the scientific instrument industry, he stated that the sector stands at a crossroads of transformation and opportunities, and elaborated on Chromai’s strategies to break through industry bottlenecks, equipping the audience with a clearer understanding of market dynamics.
Throughout the BCEIA 2025 sharing session, Zhang Xin integrated hands-on operational experience and data-driven insights to unpack core financing rationales and reveal the industry’s growth pathways. His sharing provided valuable references for all industry peers to jointly explore future development opportunities.
About Chromai
Chromai is a leading Chinese supplier of high-end scientific instruments and medical diagnostic devices. Driven by the mission to make analytical testing more efficient, accurate and user-friendly, the company adheres to independent forward R&D and continuous innovation, with cutting-edge proprietary technologies and numerous core patents. We focus on the deep integration of scientific instruments with automation and intelligence, and our products and solutions serve customers across diverse application fields worldwide.
As a national high-tech enterprise, Chromai holds memberships in organizations including China Instrument and Control Society, China Association for Instrumental Analysis and China Medical Device Industry Association. Committed to making Chinese innovations renowned globally, we strive to evolve into a Chinese tech enterprise advancing global public health and safety. We consistently boost testing efficiency, cut analytical costs and deliver tangible value to customers.
